# Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

> **NCT07225439** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Paolo Caimi, MD** · enrollment: 15 (estimated)

## Conditions studied

- Non Hodgkin Lymphoma
- B-cell Non Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Follicular Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Allogeneic NK cells
- **DRUG:** Rituximab
- **DRUG:** Tafasitamab
- **DRUG:** Interleukin-2
- **DRUG:** Fludarabine/cyclophosphamide

## Key facts

- **NCT ID:** NCT07225439
- **Lead sponsor:** Paolo Caimi, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07225439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07225439, "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07225439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*